A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

Summary

The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Background Abrams DI. Treatment options in zidovudine intolerance or failure. AIDS. 1994 Sep;8 Suppl 3:S3-7. doi: 10.1097/00002030-199409001-00002.

Drugs

Indications